Alcohol use decreased, but marijuana use and co-use of marijuana and alcohol increased from 2002 to 2018 in US young adults.
Although hospitalization risk was higher, mortality, thrombosis, and ICU admission risks were the same in patients with and without liver transplants.
Study data have identified an upward trend in premature deaths associated with alcoholic liver disease by sex and race.
Two US researchers and a British scientist have been awarded the 2020 Nobel Prize in physiology or medicine for major contributions to the fight against blood-borne hepatitis.
Overall survival is significantly lower among Black patients with colorectal liver metastases compared with other races.
Researchers analyzed the relationship between an altered gut microbiome and complications of cirrhosis and survival and sought to determine its effect on disease progression and prognosis.
The use of CPAP alone does not appear to improve hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease and obstructive sleep apnea.
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
In July 2020, the FDA Cardiovascular and Renal Drugs Advisory Committee narrowly voted 8 to 7 in favor of the approval of terlipressin for HRS-1.
Could one month on treatment albuminemia predict survival and guide treatment decisions? Investigators find out.
TERN-201 is a highly-selective semicarbazide-sensitive amino oxidase inhibitor.
Women are more likely than men to die waiting for a liver transplant.
In patients with COVID-19, hepatic injury was associated with elevated levels of IL-6, CRP, ferritin, and lactate dehydrogenase.
Simultaneous splenectomy may prevent small-for-size graft syndrome in adults with a living donor liver transplantation.
The NIS4 biomarker panel may provide a means for clinicians to avoid unnecessary liver biopsies in patients at low risk for NASH.
Female candidates for liver transplant who have portopulmonary hypertension have higher pulmonary vascular resistance, lower Model for End-Stage Liver Disease scores, and are more likely to have autoimmune liver disease, compared with male candidates.
Eight weeks of treatment with glecaprevir/pibrentasvir is both efficacious and well tolerated in treatment-naive patients with HCV.
ASCO recommends that patients with newly diagnosed cancer slated to receive systemic anticancer meds be tested for HBV by 3 tests prior to starting therapy.
New CDC guidelines recommend a test-and-treat approach for healthcare personnel who may have been exposed to acute hepatitis C virus infection at work.
Cabozantinib prolonged survival compared with placebo regardless of baseline AFP levels. Lower baseline AFP levels associated with the longest survival.